|
|
Blood, 1 July 2007, Vol. 110, No. 1, pp. 339-344.
Prepublished online as a Blood First Edition Paper on March 22, 2007; DOI 10.1182/blood-2006-09-049189.
 Previous Article | Next Article 
Submitted September 28, 2006
Accepted March 16, 2007
Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma
Yan-Yan Liu, Christophe Leboeuf, Jing-Yi Shi, Jun-Min Li, Li Wang, Yang Shen, Jose-Francisco Garcia, Zhi-Xiang Shen, Zhu Chen, Anne Janin, Sai-Juan Chen, and Wei-Li Zhao*
State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai, China
INSERM U728, Universite Paris VII, Institut d'Hematologie, Paris, France
The Monoclonal Antibodies Unit, Biotechnology Program; Spanish National Cancer Center (CNIO), Madrid, Spain
* Corresponding author; email: weili_zhao_sih{at}yahoo.com.
The positive regulatory domain I (PRDM1) is a master regulator in the differentiation of mature B lymphocytes to plasma cells. It has two isoforms, PRDM1 and PRDM1 , and is regulated by NF- B. PRDM1 protein expression was recently demonstrated in a subset of diffuse large B-cell lymphoma (DLBCL) with aggressive behavior, a type of lymphoma for which rituximab associated with chemotherapy (R-CHOP) is now widely indicated. Using laser microdissection combined with RT-PCR amplification, PRDM1 gene expression was assessed in 82 DLBCL patients. The results showed that both PRDM1 and PRDM1 transcripts were expressed in microdissected lymphoma cells only in the non-GCB subtype of DLBCL. PRDM1 gene expression was correlated with short survival time in the non-GCB patients treated with CHOP, but not with R-CHOP. In vitro, B-lymphoma cells resistant to chemotherapy expressed PRDM1. Rituximab suppressed PRDM1 expression, which was concomitant with NF-B inactivation. The value of PRDM1 expression as a prognostic marker in non-GCB DLBCL might thus be considered. This study confirms the efficiency of rituximab on DLBCL, and allows a better understanding of one of its biological actions.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
Response: Multiple role of PRDM1β involvement in diffuse large B-cell lymphoma
- Wei-Li Zhao, Anne Janin, and Sai-Juan Chen
Blood 2008 111: 2489-2490.
[Full Text]
[PDF]
-
Is early, deep free light chain response really an adverse prognostic factor?
- Angela Dispenzieri
Blood 2008 111: 2490-2491.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al.
Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers
J. Clin. Oncol.,
June 1, 2008;
26(16):
2717 - 2724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-L. Zhao, Y.-Y. Liu, Q.-L. Zhang, L. Wang, C. Leboeuf, Y.-W. Zhang, J. Ma, J.-F. Garcia, Y.-P. Song, J.-M. Li, et al.
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor
Blood,
April 1, 2008;
111(7):
3867 - 3871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Tam, M. Gomez, and K. Nie
Significance of PRDM1{beta} expression as a prognostic marker in diffuse large B-cell lymphomas
Blood,
February 15, 2008;
111(4):
2488 - 2489.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-L. Zhao, A. Janin, and S.-J. Chen
Response: Multiple role of PRDM1{beta} involvement in diffuse large B-cell lymphoma
Blood,
February 15, 2008;
111(4):
2489 - 2490.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Mora-Lopez, E. Reales, J. A. Brieva, and A. Campos-Caro
Human BSAP and BLIMP1 conform an autoregulatory feedback loop
Blood,
November 1, 2007;
110(9):
3150 - 3157.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
